Aptamers, which are minuscule nucleic acid or peptide-based molecules, have emerged as appealing contenders for cancer assessment and management due to their outstanding particularity, durability, and adaptation. Notwithstanding substantial progress, an assortment of impediments remains in the way of the transition from laboratory investigations to applications in medicine. This chapter conveys an expansive insight into aptamer-based platforms, with a concentration on their prospective applications in cancer treatment. The beneficial properties of aptamers over characteristic antibodies are discussed, particularly their straightforwardness of synthesis and adaptation, as well as the expanding involvement of nanomaterials in augmenting their purposes. Aptamers are not implemented in healthcare scenarios because of several difficulties. These consist of obstacles to establishing high target affinity and precision in a wide range of biological options, as well as issues with stability, integrity of structure, and deterioration sensitivity under physiological situations. The chapter also examines governmental constraints, the high costs of production and adaptation, and the troubles of transporting aptamers to tumor regions. To conquer these obstructions, subsequent investigations should concentrate on establishing standardized techniques for aptamer manufacturing and customization, strengthening delivery systems, and tackling regulation-related problems. The study of innovative tiny materials, as well as the incorporation of computer and artificial intelligence approaches to aptamer architecture, may provide new solutions. Aptamers can only achieve maximal effectiveness as transformative cancer screening and treatment methodologies through collaborative integrative endeavors and large-scale clinical experiments that overcome the boundary between research and medicinal implementations.